Design of amidobenzimidazole STING receptor agonists with systemic activity

Joshi M. Ramanjulu; G. Scott Pesiridis; Jingsong Yang; N.O. Concha; Robert R. Singhaus; Shuyun Zhang; Jean-Luc Tran; Patrick Moore; Stephanie Lehmann; H. Christian Eberl; Marcel Muelbaier; Jessica L. Schneck; Jim Clemens; Michael Adam; John F. Mehlmann; Joseph J. Romano; Angel Morales; James Kang; Lara K. Leister; Todd L. Graybill; Adam K. Charnley; Guosen Ye; Neysa Nevins; Kamelia Behnia; Amaya I. Wolf; Viera Kasparcova; Kelvin Nurse; Liping Wang; Ana C. Puhl; Yue Li; Michael Klein; Christopher B. Hopson; Jeffrey Guss; Marcus Bantscheff; Giovanna Bergamini; Michael Reilly; Yiqian Lian; Kevin J. Duffy; Jerry L. Adams; Kevin P. Foley; Peter J. Gough; Robert W. Marquis; James Smothers; Axel Hoos; John Bertin

doi:10.1038/s41586-018-0705-y

Design of amidobenzimidazole STING receptor agonists with systemic activity

Joshi M. Ramanjulu(GlaxoSmithKline (United States)), G. Scott Pesiridis(GlaxoSmithKline (United States)), Jingsong Yang(GlaxoSmithKline (United States)), N.O. Concha(GlaxoSmithKline (United States)), Robert R. Singhaus(GlaxoSmithKline (United States)), Shuyun Zhang(GlaxoSmithKline (United States)), Jean-Luc Tran(GlaxoSmithKline (United States)), Patrick Moore(GlaxoSmithKline (United States)), Stephanie Lehmann(GlaxoSmithKline (Germany)), H. Christian Eberl(GlaxoSmithKline (Germany)), Marcel Muelbaier(GlaxoSmithKline (Germany)), Jessica L. Schneck(GlaxoSmithKline (United States)), Jim Clemens(GlaxoSmithKline (United States)), Michael Adam(GlaxoSmithKline (United States)), John F. Mehlmann(GlaxoSmithKline (United States)), Joseph J. Romano(GlaxoSmithKline (United States)), Angel Morales(GlaxoSmithKline (United States)), James Kang(GlaxoSmithKline (United States)), Lara K. Leister(GlaxoSmithKline (United States)), Todd L. Graybill(GlaxoSmithKline (United States)), Adam K. Charnley(GlaxoSmithKline (United States)), Guosen Ye(GlaxoSmithKline (United States)), Neysa Nevins(GlaxoSmithKline (United States)), Kamelia Behnia(GlaxoSmithKline (United States)), Amaya I. Wolf(GlaxoSmithKline (United States)), Viera Kasparcova(GlaxoSmithKline (United States)), Kelvin Nurse(GlaxoSmithKline (United States)), Liping Wang(GlaxoSmithKline (United States)), Ana C. Puhl(GlaxoSmithKline (United States)), Yue Li(GlaxoSmithKline (United States)), Michael Klein(GlaxoSmithKline (United States)), Christopher B. Hopson(GlaxoSmithKline (United States)), Jeffrey Guss(GlaxoSmithKline (United States)), Marcus Bantscheff(GlaxoSmithKline (Germany)), Giovanna Bergamini(GlaxoSmithKline (Germany)), Michael Reilly(GlaxoSmithKline (United States)), Yiqian Lian(GlaxoSmithKline (United States)), Kevin J. Duffy(GlaxoSmithKline (United States)), Jerry L. Adams(GlaxoSmithKline (United States)), Kevin P. Foley(GlaxoSmithKline (United States)), Peter J. Gough(GlaxoSmithKline (United States)), Robert W. Marquis(GlaxoSmithKline (United States)), James Smothers(GlaxoSmithKline (United States)), Axel Hoos(GlaxoSmithKline (United States)), John Bertin(GlaxoSmithKline (United States))

Nature

November 6, 2018

10.1038/s41586-018-0705-y

Cited by 855

Abstract

Related Papers

No related papers found

Powered by citation graph analysis